Reading the PARTNER 3 Trial
At the ACC.19 Late-Breaking Clinical Trials session, the results of the PARTNER 3 trial comparing TAVR and SAVR in patients with low-risk aortic stenosis were presented, showing a significantly lower risk of death/stroke/rehospitalization at one year with TAVR. The results of the PARTNER 3 trial were presented and after the results were announced, the audience gave a standing ovation, with some commentators even calling it a "historical moment".
TCROSS NEWS asked Dr. Kentaro Hayashida of Keio University, who has been conducting TAVR as a Japanese proctor since the early days of its introduction, about his views on the results and future prospects.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
